Form 4: Artiva Director Sorg Acquires 27,500 Stock Options

Artiva Biotherapeutics Director Elaine K. Sorg was granted 27,500 stock options with an exercise price of $4.15, vesting over three years.

Summary

• Elaine K. Sorg, a Director of Artiva Biotherapeutics, Inc. (ARTV), acquired 27,500 Director Stock Options.
• The transaction date for the option grant was February 18, 2026.
• The exercise price for these options is $4.15 per share.
• The options have an expiration date of February 17, 2036.
• One-third of the shares vested immediately following the grant date.
• The remaining shares will vest monthly over an additional two years, commencing after February 18, 2026.
• Following this transaction, Ms. Sorg beneficially owns 27,500 derivative securities (stock options).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine and slightly positive event, as it aligns the director's interests with shareholders, though it is not a significant catalyst for the stock price.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• Equity compensation is a standard practice for attracting and retaining qualified board members in the biotechnology sector.

Negatives

• The issuance of stock options represents potential future dilution for existing shareholders if the options are exercised.

Risks

• The value of the stock options is dependent on the future market price of Artiva Biotherapeutics' common stock exceeding the $4.15 exercise price.
• If the company's stock price does not perform well, the options may not provide significant value to the holder.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction, as it is a disclosure of an insider transaction.

Industry Context

StockSavvy.ai notes that granting stock options to directors is a common practice in the biotechnology industry, serving as a key component of compensation packages designed to align leadership incentives with shareholder value creation. This particular grant is routine for a director.

Comparison to Industry Standards

• The grant of stock options to a director is a standard form of equity compensation, comparable to practices at other publicly traded biotechnology companies such as Moderna (MRNA) or BioNTech (BNTX), which frequently use equity to compensate their board members.
• The vesting schedule, with an initial immediate vest followed by monthly vesting over two years, is also a common structure aimed at retaining directors and ensuring long-term commitment.

Related Party Transactions

• The grant of stock options to Elaine K. Sorg, a Director of Artiva Biotherapeutics, Inc., constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also increased alignment of director's interests with shareholder value.
• Elaine K. Sorg (Director): Receives equity compensation, providing a direct financial incentive tied to the company's stock performance.

Next Steps

• The options will continue to vest monthly over the next two years following February 18, 2026, subject to Ms. Sorg's continued service as a director.
• Ms. Sorg may choose to exercise her vested options at any point before the expiration date of February 17, 2036.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a director and does not provide new information that would fundamentally alter the investment thesis for Artiva Biotherapeutics. While it indicates continued alignment of management interests, it is not a significant catalyst for a 'buy' or 'sell' recommendation. Investors should continue to 'hold' based on broader company fundamentals and market conditions.

Keywords

Artiva Biotherapeutics, ARTV, Stock Options, Director Compensation, Insider Transaction, Equity Grant, Biotechnology, SEC Form 4